SelectQuote, Inc. (SLQT) Stock Analysis and Metrics

Sector: Financial Services Industry: Insurance Brokers CIK: 0001794783

Market Cap 116.22 Mn

P/E 1.77

P/S 0.09

Div. Yield 0.00

ROIC (Qtr) 0.21

Total Debt (Qtr) 405.80 Mn

Revenue Growth (1y) (Qtr) 11.65

Add ratio to table...

About

SelectQuote, Inc. (SLQT) operates in the insurance industry, offering a variety of insurance products and services to its customers. The company's main business activities include distributing insurance policies, such as those for senior health, life, and automobile and home, as well as providing healthcare services, including pharmacy and other healthcare-related services. SelectQuote generates revenue through commissions earned from insurance carrier partners for policies sold on their behalf. The company's primary products and services include...

SelectQuote, Inc. (SLQT) operates in the insurance industry, offering a variety of insurance products and services to its customers. The company's main business activities include distributing insurance policies, such as those for senior health, life, and automobile and home, as well as providing healthcare services, including pharmacy and other healthcare-related services.

SelectQuote generates revenue through commissions earned from insurance carrier partners for policies sold on their behalf. The company's primary products and services include term life insurance, final expense insurance, critical illness insurance, and juvenile insurance in its Life segment; Medicare Advantage and Medicare Supplement insurance plans, prescription drug and dental, vision, and hearing plans, and critical illness products in its Senior segment; and auto, home, and specialty insurance lines in its Auto & Home segment. The company's customer base includes individuals seeking insurance products and healthcare services.

The company's business model is designed to maximize commissions collected over the life of an approved policy, referred to as policyholder lifetime value. This is achieved through the company's proprietary technology, which enables it to analyze and identify high-quality consumer leads, score and route them to the most appropriate agents, and provide personalized advice and guidance to consumers. The company's agents are highly trained and skilled in the products they sell, and the company's technology and processes are designed to enhance the customer experience, improve sales, and increase customer retention.

SelectQuote operates in a highly competitive industry, with key competitors including other insurance distributors and online insurance platforms. The company's competitive advantages include its proprietary technology, which enables it to analyze and identify high-quality consumer leads, and its highly trained and skilled agents, who provide personalized advice and guidance to consumers.

In the Life segment, SelectQuote represents approximately 20 insurance carrier partners, including Mutual of Omaha, CUNA, and Pacific Life. In the Senior segment, the company represents approximately 25 leading insurance carrier partners, including UnitedHealthcare, Humana, and Wellcare. In the Auto & Home segment, SelectQuote represents approximately 25 insurance carrier partners, including Travelers, SafeCo, and Progressive.

The market opportunity for SelectQuote is significant, with an estimated total addressable market of over $180 billion. The company estimates that its market share is less than 2.5% in each of its four segments, providing ample opportunity for growth. The company's growth strategy includes expanding its product offerings, enhancing its technology and processes, and increasing its marketing efforts to reach new customers.

In the Life segment, SelectQuote offers a range of life insurance products, including term life insurance, final expense insurance, critical illness insurance, and juvenile insurance. The company's agents are highly trained and skilled in the products they sell, and the company's technology and processes are designed to enhance the customer experience, improve sales, and increase customer retention.

The Senior segment is another important part of SelectQuote's business, offering Medicare Advantage and Medicare Supplement insurance plans, prescription drug and dental, vision, and hearing plans, and critical illness products. The company represents approximately 25 leading insurance carrier partners in this segment, including UnitedHealthcare, Humana, and Wellcare.

The Auto & Home segment is a significant part of SelectQuote's business, offering auto, home, and specialty insurance lines. The company represents approximately 25 insurance carrier partners in this segment, including Travelers, SafeCo, and Progressive.

SelectQuote's competitive strengths include its proprietary technology, highly trained and skilled agents, and strong brand awareness. The company's technology-enabled agent model is designed to maximize policyholder lifetime value, and its agents are able to provide personalized advice and guidance to consumers. The company's strong brand awareness is built on its reputation for providing high-quality products and services, and its agents are able to leverage this brand awareness to attract new customers.

Investment thesis

Bull case

SelectRx has accelerated its growth trajectory with a 26 percent year‑over‑year increase in revenue and a 17 percent rise in member count. The platform’s 30‑day medication strip and pharmacist review model has already led to a measurable 20 percent reduction in hospital days, a key metric for payers. These operational improvements translate directly into higher gross margins for the health care services segment, which currently commands a 1 percent adjusted EBITDA margin. As the pharmacy segment matures, the company is positioned to capture incremental revenue from new drug categories and enhanced MTM services, creating a durable upside that the market has not yet priced in.
The company’s three‑segment structure—Senior, Health Care Services, and Life—provides a natural hedge against cyclical swings in any single line of business. Senior policies generate high LTV commissions, while Health Care Services delivers a cash‑rich revenue stream that is largely independent of carrier commission cycles. The Life segment, though currently modest, offers a low‑cost platform that can be scaled with minimal capital outlay. This diversification reduces systemic risk exposure and improves overall earnings stability, a factor that has been underappreciated by market participants.
Agent productivity has improved by 12 percent relative to two years ago, while marketing spend per approved policy has remained stable at $326. This combination of higher output and efficient acquisition has driven the senior business to a near‑record 39 percent EBITDA margin, the fourth consecutive year above 30 percent. The CFO’s emphasis on operating cash flow growth—projected to rise 20 percent in 2026—underscores management’s focus on converting operating profitability into tangible shareholder value. The margin discipline achieved in a volatile Medicare Advantage landscape suggests a resilient business model that can withstand regulatory and carrier fluctuations.
Management’s announcement of a multiyear partnership with a major PBM has eliminated the pricing uncertainty that previously weighed on the health care services segment. The new agreement provides predictable reimbursement terms and increased visibility into drug pricing, effectively neutralizing the one‑time $20 million hit previously forecast. By locking in stable margin parameters, the company removes a significant tail risk from its earnings forecast, giving investors a clearer path to forecasted profitability. This contractual certainty is an undervalued catalyst that should be reflected in valuation multiples.
The 415 million dollar credit facility, extended to 2031, gives SelectQuote a debt maturities profile that aligns with its long‑term growth plans. The new facility reduces interest expense by up to 100 basis points, freeing capital that can be deployed toward high‑margin initiatives such as selective growth in SelectRx or targeted acquisitions. The improved balance sheet flexibility allows the company to maintain aggressive agent hiring or invest in technology upgrades without compromising liquidity, a defensive moat not fully captured by current market pricing.

SelectRx has accelerated its growth trajectory with a 26 percent year‑over‑year increase in revenue and a 17 percent rise in member count. The platform’s 30‑day medication strip and pharmacist review model has already led to a measurable 20 percent reduction in hospital days, a key metric for payers. These operational improvements translate directly into higher gross margins for the health care services segment, which currently commands a 1 percent adjusted EBITDA margin. As the pharmacy segment matures, the company is positioned to capture incremental revenue from new drug categories and enhanced MTM services, creating a durable upside that the market has not yet priced in.
The company’s three‑segment structure—Senior, Health Care Services, and Life—provides a natural hedge against cyclical swings in any single line of business. Senior policies generate high LTV commissions, while Health Care Services delivers a cash‑rich revenue stream that is largely independent of carrier commission cycles. The Life segment, though currently modest, offers a low‑cost platform that can be scaled with minimal capital outlay. This diversification reduces systemic risk exposure and improves overall earnings stability, a factor that has been underappreciated by market participants.
Agent productivity has improved by 12 percent relative to two years ago, while marketing spend per approved policy has remained stable at $326. This combination of higher output and efficient acquisition has driven the senior business to a near‑record 39 percent EBITDA margin, the fourth consecutive year above 30 percent. The CFO’s emphasis on operating cash flow growth—projected to rise 20 percent in 2026—underscores management’s focus on converting operating profitability into tangible shareholder value. The margin discipline achieved in a volatile Medicare Advantage landscape suggests a resilient business model that can withstand regulatory and carrier fluctuations.
Management’s announcement of a multiyear partnership with a major PBM has eliminated the pricing uncertainty that previously weighed on the health care services segment. The new agreement provides predictable reimbursement terms and increased visibility into drug pricing, effectively neutralizing the one‑time $20 million hit previously forecast. By locking in stable margin parameters, the company removes a significant tail risk from its earnings forecast, giving investors a clearer path to forecasted profitability. This contractual certainty is an undervalued catalyst that should be reflected in valuation multiples.
The 415 million dollar credit facility, extended to 2031, gives SelectQuote a debt maturities profile that aligns with its long‑term growth plans. The new facility reduces interest expense by up to 100 basis points, freeing capital that can be deployed toward high‑margin initiatives such as selective growth in SelectRx or targeted acquisitions. The improved balance sheet flexibility allows the company to maintain aggressive agent hiring or invest in technology upgrades without compromising liquidity, a defensive moat not fully captured by current market pricing.

Bear case

SelectQuote’s revenue and EBITDA are heavily reliant on a limited number of carrier partners, many of which have already demonstrated a willingness to reduce marketing budgets and impose headwinds. The carrier cut that lowered 2026 guidance by $20 million is a clear indicator of this concentration risk, and there is no evidence to suggest that other carriers will not follow suit. Should a similar action occur, the company’s growth trajectory could be severely hampered, creating a downward spiral in both revenue and profitability.
While the PBM agreement is presented as a one‑time stabilization measure, the company’s exposure to pharmacy reimbursement rates remains high. The health care services segment grew 26 percent in revenue, yet its adjusted EBITDA margin fell from 2 percent to a loss of 62 percent in the six‑month period, reflecting margin erosion from PBM headwinds. If reimbursement trends continue to deteriorate, the segment’s profitability could deteriorate further, undermining the company’s overall earnings profile.
The company reports a high rate of policy terminations—approximately 7 percent of in‑force policies—significantly above the historical average. This trend erodes the lifetime value of commissions and reduces the predictability of future cash flows. Even though the firm boasts a strong recapture rate, the persistent churn indicates that the market may not be fully priced for the long‑term decline in commission LTV.
Regulatory uncertainty looms large, particularly with the upcoming CMS advance rate notice and potential changes to Medicare Advantage reimbursement. The company’s management acknowledges that the advanced rates may not reflect rising utilization costs, implying that future adjustments could be unfavorable. A tightening of regulations could further compress margins across all segments, creating an adverse operating environment that management has not fully quantified.
Direct‑to‑consumer carriers are gaining traction, and some of SelectQuote’s carrier partners have already reduced marketing spend to encourage this shift. As carriers invest more heavily in digital channels, the company's traditional agent‑based model may face declining relevance, especially among tech‑savvy seniors. If the industry moves away from the broker‑mediated approach, SelectQuote could see a sharp decline in policy acquisition volumes, eroding its revenue base.

SelectQuote’s revenue and EBITDA are heavily reliant on a limited number of carrier partners, many of which have already demonstrated a willingness to reduce marketing budgets and impose headwinds. The carrier cut that lowered 2026 guidance by $20 million is a clear indicator of this concentration risk, and there is no evidence to suggest that other carriers will not follow suit. Should a similar action occur, the company’s growth trajectory could be severely hampered, creating a downward spiral in both revenue and profitability.
While the PBM agreement is presented as a one‑time stabilization measure, the company’s exposure to pharmacy reimbursement rates remains high. The health care services segment grew 26 percent in revenue, yet its adjusted EBITDA margin fell from 2 percent to a loss of 62 percent in the six‑month period, reflecting margin erosion from PBM headwinds. If reimbursement trends continue to deteriorate, the segment’s profitability could deteriorate further, undermining the company’s overall earnings profile.
The company reports a high rate of policy terminations—approximately 7 percent of in‑force policies—significantly above the historical average. This trend erodes the lifetime value of commissions and reduces the predictability of future cash flows. Even though the firm boasts a strong recapture rate, the persistent churn indicates that the market may not be fully priced for the long‑term decline in commission LTV.
Regulatory uncertainty looms large, particularly with the upcoming CMS advance rate notice and potential changes to Medicare Advantage reimbursement. The company’s management acknowledges that the advanced rates may not reflect rising utilization costs, implying that future adjustments could be unfavorable. A tightening of regulations could further compress margins across all segments, creating an adverse operating environment that management has not fully quantified.
Direct‑to‑consumer carriers are gaining traction, and some of SelectQuote’s carrier partners have already reduced marketing spend to encourage this shift. As carriers invest more heavily in digital channels, the company's traditional agent‑based model may face declining relevance, especially among tech‑savvy seniors. If the industry moves away from the broker‑mediated approach, SelectQuote could see a sharp decline in policy acquisition volumes, eroding its revenue base.

Segments Breakdown of Revenue (2025)

Equity Components Breakdown of Revenue (2025)

Peer comparison

Companies in the Insurance Brokers

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	AON	Aon plc	69.97 Bn	18.94	4.07	15.25 Bn
2	AJG	Arthur J. Gallagher & Co.	55.32 Bn	37.05	3.93	12.74 Bn
3	WTW	Willis Towers Watson Plc	28.37 Bn	16.87	2.97	5.76 Bn
4	BRO	Brown & Brown, Inc.	20.43 Bn	19.14	3.46	1.03 Bn
5	ERIE	Erie Indemnity Co	11.46 Bn	20.66	2.82	-
6	CRVL	Corvel Corp	2.79 Bn	26.39	2.96	-
7	ARX	Accelerant Holdings	2.53 Bn	-2.09	50.89	-
8	GSHD	Goosehead Insurance, Inc.	1.06 Bn	38.45	2.89	0.29 Bn

Research Tools

SelectQuote, Inc. (NYSE: SLQT)

About

Investment thesis

Bull case

Bear case

Segments Breakdown of Revenue (2025)

Equity Components Breakdown of Revenue (2025)

Peer comparison

Research Tools

SelectQuote, Inc. (NYSE: SLQT)

About

Investment thesis

Bull case

Bear case

Segments Breakdown of Revenue (2025)

Equity Components Breakdown of Revenue (2025)

Peer comparison

Create an account

Sign In

Reset Password